| Trial ID: | L0556 |
| Source ID: | NCT05577507
|
| Associated Drug: |
Cholestyramine Resin 4000 Mg [Questran]
|
| Title: |
Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases|Hemodialysis Complication|Hyperphosphatemia
|
| Interventions: |
DRUG: Cholestyramine Resin 4000 MG [Questran]|DRUG: Calcium Carbonate 500 MG Oral Tablet
|
| Outcome Measures: |
Primary: serum phosphate level, measuring serum phosphate level at baseline and after 8 weeks trial period to evaluate serum phosphate reduction by cholestyramine, 8 weeks trial period|serum calcium level, measuring serum calcium level at baseline and after 8 weeks trial period to evaluate serum calcium reduction by cholestyramine, 8 weeks trial period|iPTH, measuring iPTH level at baseline and after 8 weeks trial period to evaluate iPTH reduction by cholestyramine, 8 weeks trial period | Secondary: Lipid Profile ( triglyceride level , LDL ,HDL ,Total cholesterol ), measuring LDL , total cholesterol reduction after using cholestyramine for 8 weeks trial period, 8 weeks trial period
|
| Sponsor/Collaborators: |
Sponsor: Ain Shams University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-03-30
|
| Completion Date: |
2023-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-06
|
| Locations: |
Ain Shams university, Cairo, 11511, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05577507
|
